These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14744972)

  • 1. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention.
    Takamori N; Azuma H; Kato M; Hashizume S; Aihara K; Akaike M; Tamura K; Matsumoto T
    Circulation; 2004 Feb; 109(4):481-6. PubMed ID: 14744972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.
    Huang SS; Huang PH; Chen YH; Sung SH; Chiang KH; Chen JW; Lin SJ
    Coron Artery Dis; 2008 Dec; 19(8):597-602. PubMed ID: 18971786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
    Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis.
    Kitta Y; Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Ichigi Y; Mende A; Kugiyama K
    J Am Coll Cardiol; 2005 Aug; 46(4):648-55. PubMed ID: 16098430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting.
    Schillinger M; Exner M; Sabeti S; Mlekusch W; Amighi J; Handler S; Quehenberger P; Kalifeh N; Wagner O; Minar E
    Thromb Haemost; 2004 Nov; 92(5):1108-13. PubMed ID: 15543340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin cofactor II modulates the response to vascular injury.
    Tollefsen DM
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients.
    Xu B; Li JJ; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2006 Apr; 119(7):533-8. PubMed ID: 16620692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stenting alone versus debulking and debulking plus stent in branch ostial lesions of native coronary arteries.
    Chung CM; Nakamura S; Tanaka K; Tanigawa J; Kitano K; Akiyama T; Matoba Y; Katoh O
    Heart Vessels; 2004 Sep; 19(5):213-20. PubMed ID: 15372295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
    Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
    Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
    Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
    Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between preheparin lipoprotein lipase mass concentration in serum and bare metal stent restenosis.
    Hitsumoto T; Takahashi M; Iizuka T; Shirai K
    J Cardiol; 2006 Aug; 48(2):65-73. PubMed ID: 16948449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation.
    Tutar E; Ozcan M; Kilickap M; Gülec S; Aras O; Pamir G; Oral D; Dandelet L; Key NS
    Circulation; 2003 Sep; 108(13):1581-4. PubMed ID: 12975255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pulse pressure as a predictor of restenosis after percutaneous transluminal coronary angioplasty].
    Jankowski P; Kawecka-Jaszcz K; Bryniarski L; Czarnecka D; Zabojszcz M; Styczkiewicz M
    Przegl Lek; 2001; 58(12):1025-8. PubMed ID: 12041014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus.
    Sukhija R; Aronow WS; Sureddi R; Aleti S; Molavi B; Sachdeva R; Mehta JL
    Am J Cardiol; 2007 Sep; 100(5):777-80. PubMed ID: 17719319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism.
    Gross CM; Perrot A; Geier C; Posch MG; Hassfeld S; Kramer J; Schmidt S; Derer W; Dietz R; Ozcelik C
    J Invasive Cardiol; 2007 Jun; 19(6):261-4. PubMed ID: 17541127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation.
    Lee SH; Park JS; Shin DG; Kim YJ; Hong GR; Kim W; Shim BS
    Am J Cardiol; 2007 Aug; 100(4):627-30. PubMed ID: 17697818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents in bifurcation lesions: to stent one branch or both?
    Assali AR; Assa HV; Ben-Dor I; Teplitsky I; Solodky A; Brosh D; Fuchs S; Kornowski R
    Catheter Cardiovasc Interv; 2006 Dec; 68(6):891-6. PubMed ID: 17086532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial.
    Tamai H; Berger PB; Tsuchikane E; Suzuki T; Nishikawa H; Aizawa T; Fujii K; Nozaki Y; Kyo E; Kobayashi T; Reiber J; Van Weert AW;
    Am Heart J; 2004 Mar; 147(3):E9. PubMed ID: 14999211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.